Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, ...

Diazoxide choline extended-release tablets demonstrated favorable safety profile across 4 years among patients with Prader-Willi Syndrome.

Veligrotug demonstrated significant improvements in proptosis, diplopia, and clinical activity score among patients with active thyroid eye disease.

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

Early abdominal CT may be warranted among patients with unknown or uncertain biochemical screening results for primary aldosteronism.

Thyroid cancer burden attributable to high BMI was increasing between 1990 and 2021 in the US, especially among men and older ...

Glucopilot dynamic dosing algorithm was associated with improved glycemic control especially among subgroups with ...

Adrenal adenomas were associated with attenuated weight loss among patients with obesity or overweight using GLP-1 or GIP/GLP ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

Adolescents with PCOS demonstrated comparable weight loss to their reproductively normal peers after undergoing bariatric ...

COCPs were associated with improved obesity outcomes among patients with hyperandrogenic PCOS, but metformin added little ...

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.